Comparing of ChromaDex Corporation (CDXC) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

We are comparing ChromaDex Corporation (NASDAQ:CDXC) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChromaDex Corporation 31.56M 6.55 33.32M -0.63 0.00
Jazz Pharmaceuticals plc 1.89B 4.07 447.10M 5.93 22.69

We can see in table 1 the earnings per share, gross revenue and valuation of ChromaDex Corporation and Jazz Pharmaceuticals plc.


Table 2 demonstrates the net margins, return on equity and return on assets of ChromaDex Corporation and Jazz Pharmaceuticals plc.

Net Margins Return on Equity Return on Assets
ChromaDex Corporation -105.58% -77.8% -61.9%
Jazz Pharmaceuticals plc 23.66% 15.2% 8.2%

Risk & Volatility

ChromaDex Corporation has a 1.1 beta, while its volatility is 10.00% which is more volatile than Standard & Poor’s 500. From a competition point of view, Jazz Pharmaceuticals plc has a 1.23 beta which is 23.00% more volatile compared to Standard & Poor’s 500.


The Current Ratio and Quick Ratio of ChromaDex Corporation are 3.2 and 2.7 respectively. Its competitor Jazz Pharmaceuticals plc’s Current Ratio is 4.3 and its Quick Ratio is 4.2. Jazz Pharmaceuticals plc can pay off short and long-term obligations better than ChromaDex Corporation.

Analyst Recommendations

The next table highlights the given recommendations and ratings for ChromaDex Corporation and Jazz Pharmaceuticals plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ChromaDex Corporation 0 0 0 0.00
Jazz Pharmaceuticals plc 0 3 5 2.63

Competitively Jazz Pharmaceuticals plc has an average price target of $172.88, with potential upside of 28.25%.

Insider & Institutional Ownership

ChromaDex Corporation and Jazz Pharmaceuticals plc has shares owned by institutional investors as follows: 17.7% and 90.8%. 2.3% are ChromaDex Corporation’s share owned by insiders. Competitively, 2.5% are Jazz Pharmaceuticals plc’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ChromaDex Corporation -6.93% 4.8% -2.24% -22.96% -33.4% 1.75%
Jazz Pharmaceuticals plc 6.52% 6.82% -8.16% -21.57% -4.4% 8.49%

For the past year ChromaDex Corporation has weaker performance than Jazz Pharmaceuticals plc


Jazz Pharmaceuticals plc beats ChromaDex Corporation on 11 of the 12 factors.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with ParkinsonÂ’s disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.